Nebraska 109th Legislature (2025-2026) Status: Enacted

LB 795 — Designate bromazolam as a controlled substance under the Uniform Controlled Substances Act, correct the spelling of certain controlled substances, and enhance penalties for certain controlled substance offenses involving fentanyl

Last action — Provisions/portions of LB817 amended into LB795 by AM2092

  1. ✓
    Introduced
  2. ✓
    In Committee
  3. ✓
    Passed Legislature
  4. ✓
    To Executive
  5. 5
    Enacted

This bill has been enacted into law. Introduced January 07, 2026. Enacted.

Signed by Governor Jim Pillen (Republican) on March 03, 2026.

Odds of enactment

High chance

Based on the sponsor, cosponsors, and committee posture, this bill has a high chance of becoming law.

Upgrade to see the exact probability and what's driving it.

A statistical estimate from our own model of past outcomes — an insight, not a guarantee. Policymaking is volatile.

Prognosis

Advancing 54% · moderate confidence

  • Enacted

    Current position in the legislative process.

  • 1 sponsor

    1 primary, 0 co-sponsors signed on.

  • Mixed recorded votes

    3 passed, 8 failed in recorded votes so far.

Based on stage, sponsorship breadth, committee status, recorded votes, and cross-state momentum — a description of the observable signals, not a prediction.

Bill Text

What changed in the latest version

1542 added · 1683 removed

Plain-language change summary

The legislative amendments to Bill LB 795 include the addition of bromazolam as a controlled substance and an enhancement of penalties for offenses involving fentanyl. Additionally, the updates correct the spelling of certain drug names to ensure clarity in the law. These changes are important because they aim to address rising concerns about the safety and regulation of substances related to drug use and trafficking, particularly as opioids like fentanyl continue to pose significant public health risks.

→
Previous
Latest
LB795 LB795 2026 LEGISLATURE OF NEBRASKA ONE HUNDRED NINTH LEGISLATURE SECOND SESSION LEGISLATIVE BILL 795 FINAL READING   Introduced by DeKay, 40.
LB795 LB795 2026 LEGISLATIVE BILL 795 Approved by the Governor March 3, 2026   Introduced by DeKay, 40.
Read first time January 07, 2026 Committee:
  A BILL FOR AN ACT relating to crimes and offenses;
Judiciary A BILL FOR AN ACT relating to crimes and offenses;
Be it enacted by the people of the State of Nebraska, -1- LB795 LB795 2026 Section 1.
Be it enacted by the people of the State of Nebraska, Section 1.
-2- LB795 LB795 2026 (19) Dioxaphetyl butyrate;
(19) Dioxaphetyl butyrate;
(46) 3-Methylfentanyl, N-(3-methyl-1-(2-phenylethyl)-4-piperidyl)-N- phenylpropanamide, its optical and geometric isomers, salts, and salts of -3- LB795 LB795 2026 isomers;
(46) 3-Methylfentanyl, N-(3-methyl-1-(2-phenylethyl)-4-piperidyl)-N- phenylpropanamide, its optical and geometric isomers, salts, and salts of isomers;
(48) PEPAP, 1-(2-phenethyl)-4-phenyl-4-acetoxypiperidine, its optical isomers, salts, and salts of isomers;
(48) PEPAP, 1-(2-phenethyl)-4-phenyl-4-acetoxypiperidine, its optical -1- LB795 LB795 2026 isomers, salts, and salts of isomers;
(52) Beta-hydroxyfentanyl, N-(1-(2-hydroxy-2-phenethyl)-4- piperidinyl)-N-phenylpropanamide, its optical isomers, salts, and salts of isomers;
(52) Beta-hydroxyfentanyl, N-(1-(2-hydroxy-2-phenethyl)-4-piperidinyl)-N- phenylpropanamide, its optical isomers, salts, and salts of isomers;
(54) 3-methylthiofentanyl, N-(3-methyl-1-(2-thienyl)ethyl-4- piperidinyl)-N-phenylpropanamide, its optical and geometric isomers, salts, and salts of isomers;
(54) 3-methylthiofentanyl, N-(3-methyl-1-(2-thienyl)ethyl-4-piperidinyl)- N-phenylpropanamide, its optical and geometric isomers, salts, and salts of isomers;
-4- LB795 LB795 2026 (59) 4-Fluoroisobutyryl Fentanyl;
(59) 4-Fluoroisobutyryl Fentanyl;
N-(2-fluorophenyl)-N-(1-phenethylpiperidin-4- yl) propionamide;
N-(2-fluorophenyl)-N-(1-phenethylpiperidin-4-yl) propionamide;
-5- LB795 LB795 2026 (88) Ortho-Methyl Methoxyacetyl Fentanyl;
(88) Ortho-Methyl Methoxyacetyl Fentanyl;
(94) Meta-Fluorofentanyl (N-(3-fluorophenyl)-N-(1- phenethylpiperidin-4-yl)propionamide);
(94) Meta-Fluorofentanyl (N-(3-fluorophenyl)-N-(1-phenethylpiperidin-4- yl)propionamide);
(97) 3-Furanyl fentanyl (N-(1-phenethylpiperidin-4-yl)-N- phenylfuran-3-carboxamide);
(97) 3-Furanyl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-phenylfuran-3- carboxamide);
(98) 2',5'-Dimethoxyfentanyl (N-(1-(2,5- dimethoxyphenethyl)piperidin-4-yl)-N-phenylpropionamide);
(98) 2',5'-Dimethoxyfentanyl (N-(1-(2,5-dimethoxyphenethyl)piperidin-4- yl)-N-phenylpropionamide);
(101) Alpha-Methylbutyryl fentanyl (2-methyl-N-(1- phenethylpiperidin-4-yl)-N-phenylbutanamide);
(101) Alpha-Methylbutyryl fentanyl (2-methyl-N-(1-phenethylpiperidin-4- yl)-N-phenylbutanamide);
(103) Butonitazene (2-(2-(4-butoxybenzyl)-5-nitro-1H-benzimidazol-1- yl)-N,N-diethylethan-1-amine);
(103) Butonitazene (2-(2-(4-butoxybenzyl)-5-nitro-1H-benzimidazol-1-yl)- N,N-diethylethan-1-amine);
(104) Flunitazene (N,N-diethyl-2-(2-(4-fluorobenzyl)-5-nitro-1H- benzimidazol-1-yl)ethan-1-amine);
(104) Flunitazene (N,N-diethyl-2-(2-(4-fluorobenzyl)-5-nitro-1H- -2- LB795 LB795 2026 benzimidazol-1-yl)ethan-1-amine);
2-(2-(4-ethoxybenzyl)-1H- -6- LB795 LB795 2026 benzimidazol-1-yl)-N,N-diethylethan-1-amine;
2-(2-(4-ethoxybenzyl)-1H- benzimidazol-1-yl)-N,N-diethylethan-1-amine;
(109) 1-(2-methyl-4-(3-phenylprop-2-en-1-yl)piperazin-1-yl)butan-1- one (commonly known as 2-Methyl AP-237);
(109) 1-(2-methyl-4-(3-phenylprop-2-en-1-yl)piperazin-1-yl)butan-1-one (commonly known as 2-Methyl AP-237);
-7- LB795 LB795 2026 (2) Acetyldihydrocodeine;
(2) Acetyldihydrocodeine;
3-(2- dimethylaminoethyl)-5-indolol;
3-(2-dimethylaminoethyl)-5- indolol;
5-hydroxy-N,N- -8- LB795 LB795 2026 dimethyltryptamine;
5-hydroxy-N,N-dimethyltryptamine;
4-bromo-2,5-dimethoxy-alpha- methylphenethylamine;
4-bromo-2,5-dimethoxy-alpha-methylphenethylamine;
1-(4-Methoxyphenyl)-N-methylpropan-2- amine, PMMA, and 4-MMA;
1-(4-Methoxyphenyl)-N-methylpropan-2-amine, PMMA, and 4- MMA;
7-Ethyl-6,6beta,7,8,9,10,12,13-octahydro-2-methoxy-6,9- methano-5H-pyrido (1',2':1,2) azepino (5,4-b) indole;
7-Ethyl-6,6beta,7,8,9,10,12,13-octahydro-2-methoxy-6,9-methano-5H-pyrido (1',2':1,2) azepino (5,4-b) indole;
(9) Mescaline;
-3- LB795 LB795 2026 (9) Mescaline;
(14) Tetrahydrocannabinols, including, but not limited to, synthetic -9- LB795 LB795 2026 equivalents of the substances contained in the plant or in the resinous extractives of cannabis, sp.
(14) Tetrahydrocannabinols, including, but not limited to, synthetic equivalents of the substances contained in the plant or in the resinous extractives of cannabis, sp.
2-thienyl analog of phencyclidine;
2- thienyl analog of phencyclidine;
3-Hexyl-1-hydroxy-7,8,9,10-tetrahydro-6,6,9-trimethyl-6H- dibenzo(b,d)pyran;
3-Hexyl-1-hydroxy-7,8,9,10-tetrahydro-6,6,9-trimethyl-6H-dibenzo(b,d)pyran;
1-(1-phenylcyclohexyl)- pyrrolidine;
1-(1-phenylcyclohexyl)-pyrrolidine;
-10- LB795 LB795 2026 alpha-ET;
alpha-ET;
and/or synthetic substances, derivatives, and their isomers with similar chemical structure and -11- LB795 LB795 2026 pharmacological activity such as the following:
and/or synthetic substances, derivatives, and their isomers with similar chemical structure and pharmacological activity such as the following:
Any compound containing a 3-(1- naphthoyl)indole structure with substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl, alkenyl, halobenzyl, benzyl, cycloalkylmethyl, cycloalkylethyl, 2-(4-morpholinyl)ethyl group, cyanoalkyl, 1-(N-methyl-2-piperidinyl)methyl, 1-(N-methyl-2- pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, or tetrahydropyranylmethyl group, whether or not further substituted in or on any of the listed ring systems to any extent;
Any compound containing a 3-(1-naphthoyl)indole structure with substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl, alkenyl, halobenzyl, benzyl, cycloalkylmethyl, cycloalkylethyl, 2-(4-morpholinyl)ethyl group, cyanoalkyl, 1-(N-methyl-2- piperidinyl)methyl, 1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3- morpholinyl)methyl, or tetrahydropyranylmethyl group, whether or not further -4- LB795 LB795 2026 substituted in or on any of the listed ring systems to any extent;
Any compound containing a 1 H-indol-3- yl-(1-naphthyl)methane structure with substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl, alkenyl, halobenzyl, benzyl, cycloalkylmethyl, cycloalkylethyl, 2-(4-morpholinyl)ethyl group, cyanoalkyl, 1-(N-methyl-2-piperidinyl)methyl, 1-(N-methyl-2- pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, or tetrahydropyranylmethyl group, whether or not further substituted in or on any of the listed ring systems to any extent;
Any compound containing a 1 H-indol-3-yl-(1- naphthyl)methane structure with substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl, alkenyl, halobenzyl, benzyl, cycloalkylmethyl, cycloalkylethyl, 2-(4-morpholinyl)ethyl group, cyanoalkyl, 1-(N-methyl-2- piperidinyl)methyl, 1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3- morpholinyl)methyl, or tetrahydropyranylmethyl group, whether or not further substituted in or on any of the listed ring systems to any extent;
Any compound containing a 3-(1- naphthoyl)pyrrole structure with substitution at the nitrogen atom of the pyrrole ring by an alkyl, haloalkyl, alkenyl, halobenzyl, benzyl, cycloalkylmethyl, cycloalkylethyl, 2-(4-morpholinyl)ethyl group, cyanoalkyl, 1-(N-methyl-2-piperidinyl)methyl, 1-(N-methyl-2- pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, or tetrahydropyranylmethyl group, whether or not further substituted in or on any of the listed ring systems to any extent;
Any compound containing a 3-(1-naphthoyl)pyrrole structure with substitution at the nitrogen atom of the pyrrole ring by an alkyl, haloalkyl, alkenyl, halobenzyl, benzyl, cycloalkylmethyl, cycloalkylethyl, 2-(4-morpholinyl)ethyl group, cyanoalkyl, 1-(N-methyl-2- piperidinyl)methyl, 1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3- morpholinyl)methyl, or tetrahydropyranylmethyl group, whether or not further substituted in or on any of the listed ring systems to any extent;
Any compound containing a -12- LB795 LB795 2026 naphthylideneindene structure with substitution at the 3-position of the indene ring by an alkyl, haloalkyl, alkenyl, halobenzyl, benzyl, cycloalkylmethyl, cycloalkylethyl, 2-(4-morpholinyl)ethyl group, cyanoalkyl, 1-(N-methyl-2-piperidinyl)methyl, 1-(N-methyl-2- pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, or tetrahydropyranylmethyl group, whether or not further substituted in or on any of the listed ring systems to any extent;
Any compound containing a naphthylideneindene structure with substitution at the 3-position of the indene ring by an alkyl, haloalkyl, alkenyl, halobenzyl, benzyl, cycloalkylmethyl, cycloalkylethyl, 2-(4-morpholinyl)ethyl group, cyanoalkyl, 1-(N-methyl-2-piperidinyl)methyl, 1- (N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, or tetrahydropyranylmethyl group, whether or not further substituted in or on any of the listed ring systems to any extent;
Any compound containing a 3- phenylacetylindole structure with substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl, alkenyl, halobenzyl, benzyl, cycloalkylmethyl, cycloalkylethyl, 2-(4-morpholinyl)ethyl group, cyanoalkyl, 1-(N-methyl-2-piperidinyl)methyl, 1-(N-methyl-2- pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, or tetrahydropyranylmethyl group, whether or not further substituted in or on any of the listed ring systems to any extent;
Any compound containing a 3-phenylacetylindole structure with substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl, alkenyl, halobenzyl, benzyl, cycloalkylmethyl, cycloalkylethyl, 2-(4-morpholinyl)ethyl group, cyanoalkyl, 1-(N-methyl-2- piperidinyl)methyl, 1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3- morpholinyl)methyl, or tetrahydropyranylmethyl group, whether or not further substituted in or on any of the listed ring systems to any extent;
Any compound containing a 2-(3- hydroxycyclohexyl)phenol structure with substitution at the 5-position of the phenolic ring by an alkyl, haloalkyl, alkenyl, halobenzyl, benzyl, cycloalkylmethyl, cycloalkylethyl, 2-(4-morpholinyl)ethyl group, cyanoalkyl, 1-(N-methyl-2-piperidinyl)methyl, 1-(N-methyl-2- pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, or tetrahydropyranylmethyl group, whether or not substituted in or on any of the listed ring systems to any extent;
Any compound containing a 2-(3- hydroxycyclohexyl)phenol structure with substitution at the 5-position of the phenolic ring by an alkyl, haloalkyl, alkenyl, halobenzyl, benzyl, cycloalkylmethyl, cycloalkylethyl, 2-(4-morpholinyl)ethyl group, cyanoalkyl, 1- (N-methyl-2-piperidinyl)methyl, 1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N- methyl-3-morpholinyl)methyl, or tetrahydropyranylmethyl group, whether or not substituted in or on any of the listed ring systems to any extent;
Any compound containing a 3-(benzoyl)indole structure with substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl, alkenyl, halobenzyl, benzyl, cycloalkylmethyl, cycloalkylethyl, 2-(4-morpholinyl)ethyl group, cyanoalkyl, 1-(N-methyl-2- piperidinyl)methyl, 1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3- morpholinyl)methyl, or tetrahydropyranylmethyl group, whether or not further substituted in or on any of the listed ring systems to any extent;
Any compound containing a 3-(benzoyl)indole structure with substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl, alkenyl, halobenzyl, benzyl, cycloalkylmethyl, cycloalkylethyl, 2-(4-morpholinyl)ethyl group, cyanoalkyl, 1-(N-methyl-2-piperidinyl)methyl, 1- (N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, or tetrahydropyranylmethyl group, whether or not further substituted in or on any of the listed ring systems to any extent;
Show all 158 changed rows (118 more)
Previous
Latest
-13- LB795 LB795 2026 (I) Adamantoylindoles:
(I) Adamantoylindoles:
Any compound containing a 3-adamantoylindole structure with substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl, cyanoalkyl, alkenyl, halobenzyl, benzyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl, 1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3- morpholinyl)methyl, or tetrahydropyranylmethyl group, whether or not further substituted in or on any of the listed ring systems to any extent;
Any compound containing a 3-adamantoylindole structure with substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl, cyanoalkyl, alkenyl, halobenzyl, benzyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl, 1- (N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, or tetrahydropyranylmethyl group, whether or not further substituted in or on any of the listed ring systems to any extent;
Any compound containing a 3- tetramethylcyclopropanoylindole structure with substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl, cyanoalkyl, alkenyl, halobenzyl, benzyl, cycloalkylmethyl, cycloalkylethyl, 1-(N- methyl-2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl, 1-(N-methyl-2- pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, or tetrahydropyranylmethyl group, whether or not further substituted in or on any of the listed ring systems to any extent;
Any compound containing a 3- tetramethylcyclopropanoylindole structure with substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl, cyanoalkyl, alkenyl, halobenzyl, benzyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2- piperidinyl)methyl, 2-(4-morpholinyl)ethyl, 1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, or tetrahydropyranylmethyl group, whether or not further substituted in or on any of the listed ring systems to any extent;
Any compound containing a 1-indole-3- carboxamide structure with substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl, cyanoalkyl, alkenyl, halobenzyl, benzyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2- piperidinyl)methyl, 2-(4-morpholinyl)ethyl, 1-(N-methyl-2- pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, or tetrahydropyranylmethyl group, substitution at the carboxamide group by an alkyl, methoxy, benzyl, propionaldehyde, adamantyl, 1-naphthyl, phenyl, aminooxoalkyl group, or quinolinyl group, whether or not further substituted in or on any of the listed ring systems to any extent or to the adamantyl, 1-mapthyl, phenyl, aminooxoalkyl, benzyl, or propionaldehyde groups to any extent;
Any compound containing a 1-indole-3-carboxamide structure with substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl, cyanoalkyl, alkenyl, halobenzyl, benzyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl, 1- (N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, or tetrahydropyranylmethyl group, substitution at the carboxamide group by an alkyl, methoxy, benzyl, propionaldehyde, adamantyl, 1-naphthyl, phenyl, aminooxoalkyl group, or quinolinyl group, whether or not further substituted in or on any of the listed ring systems to any extent or to the adamantyl, 1- mapthyl, phenyl, aminooxoalkyl, benzyl, or propionaldehyde groups to any extent;
Any compound containing a 1-indole-3- carboxylate structure with substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl, cyanoalkyl, alkenyl, halobenzyl, -14- LB795 LB795 2026 benzyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2- piperidinyl)methyl, 2-(4-morpholinyl)ethyl, 1-(N-methyl-2- pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, or tetrahydropyranylmethyl group, substitution at the carboxylate group by an alkyl, methoxy, benzyl, propionaldehyde, adamantyl, 1-naphthyl, phenyl, aminooxoalkyl group, or quinolinyl group, whether or not further substituted in or on any of the listed ring systems to any extent or to the adamantyl, 1-mapthyl, phenyl, aminooxoalkyl, benzyl, or propionaldehyde groups to any extent;
Any compound containing a 1-indole-3-carboxylate structure with substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl, cyanoalkyl, alkenyl, halobenzyl, benzyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl, 1- (N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, or tetrahydropyranylmethyl group, substitution at the carboxylate group by an alkyl, methoxy, benzyl, propionaldehyde, adamantyl, 1-naphthyl, phenyl, aminooxoalkyl group, or quinolinyl group, whether or not further substituted in or on any of the listed ring systems to any extent or to the adamantyl, 1- mapthyl, phenyl, aminooxoalkyl, benzyl, or propionaldehyde groups to any extent;
and (M) Any nonnaturally occurring substance, chemical compound, mixture, or preparation, not specifically listed elsewhere in these schedules and which is not approved for human consumption by the federal Food and Drug Administration, containing or constituting a cannabinoid receptor agonist as defined in section 28-401;
and (M) Any nonnaturally occurring substance, chemical compound, mixture, or preparation, not specifically listed elsewhere in these schedules and which is not approved for human consumption by the federal Food and Drug Administration, containing or constituting a cannabinoid receptor agonist as defined in section -5- LB795 LB795 2026 28-401;
(29) Zipeprol 1-methoxy-3-[4-(2-methoxy-2-phenylethyl)piperazin-1- yl]-1-phenylpropan-2-ol, including its isomers, esters, ethers, salts, and salts of isomers, esters, and ethers, whenever the existence of such isomers, esters, ethers, and salts is possible within the specific chemical designation;
(29) Zipeprol 1-methoxy-3-[4-(2-methoxy-2-phenylethyl)piperazin-1-yl]-1- phenylpropan-2-ol, including its isomers, esters, ethers, salts, and salts of isomers, esters, and ethers, whenever the existence of such isomers, esters, ethers, and salts is possible within the specific chemical designation;
-15- LB795 LB795 2026 (A) Substitution of the phenyl ring by any halo, hydroxyl, alkyl, trifluoromethyl, alkoxy, or alkylthio groups;
(A) Substitution of the phenyl ring by any halo, hydroxyl, alkyl, trifluoromethyl, alkoxy, or alkylthio groups;
(i) 2-(4-Chloro-2,5-dimethoxyphenyl)ethanamine, which is also known as 2C-C or 2,5-Dimethoxy-4-chlorophenethylamine;
(i) 2-(4-Chloro-2,5-dimethoxyphenyl)ethanamine, which is also known as 2C- C or 2,5-Dimethoxy-4-chlorophenethylamine;
-16- LB795 LB795 2026 (xiv) 1-(4-chloro-2,5-dimethoxy-phenyl)propan-2-amine, which is also known as DOC or 2,5-Dimethoxy-4-chloroamphetamine;
(xiv) 1-(4-chloro-2,5-dimethoxy-phenyl)propan-2-amine, which is also known as DOC or 2,5-Dimethoxy-4-chloroamphetamine;
25B- NBOMe or 2,5-Dimethoxy-4-bromo-N-(2-methoxybenzyl)phenethylamine;
25B-NBOMe or 2,5-Dimethoxy-4-bromo-N-(2-methoxybenzyl)phenethylamine;
25I- NBOMe or 2,5-Dimethoxy-4-iodo-N-(2-methoxybenzyl)phenethylamine;
25I-NBOMe or 2,5-Dimethoxy-4-iodo-N-(2-methoxybenzyl)phenethylamine;
or 25C-NBOMe or 2,5-Dimethoxy-4-chloro-N-(2-methoxybenzyl)phenethylamine;
or 25C- NBOMe or 2,5-Dimethoxy-4-chloro-N-(2-methoxybenzyl)phenethylamine;
(xxii) N-(2-Methoxybenzyl)-1-(8-bromo-2,3,6,7- tetrahydrobenzo[1,2- b:4,5-b']difuran-4-yl)-2-aminoethane, which is also known as 2C-B-FLY- NBOMe;
(xxii) N-(2-Methoxybenzyl)-1-(8-bromo-2,3,6,7- tetrahydrobenzo[1,2-b:4,5- b']difuran-4-yl)-2-aminoethane, which is also known as 2C-B-FLY-NBOMe;
(xxiii) 1-(4-Bromofuro[2,3-f][1]benzofuran-8-yl)propan-2-amine, which is also known as bromo-benzodifuranylisopropylamine or bromo- dragonFLY;
(xxiii) 1-(4-Bromofuro[2,3-f][1]benzofuran-8-yl)propan-2-amine, which is also known as bromo-benzodifuranylisopropylamine or bromo-dragonFLY;
(xxvii) 5-(2-Aminopropyl)-2,3-dihydrobenzofuran, which is also known -17- LB795 LB795 2026 as 5-APDB;
(xxvii) 5-(2-Aminopropyl)-2,3-dihydrobenzofuran, which is also known as 5- APDB;
(xxix) 2,5-dimethoxy-amphetamine, which is also known as 2,5- dimethoxy-a-methylphenethylamine 2, 5-dimethoxy-a-methylphenethylamine;
(xxix) 2,5-dimethoxy-amphetamine, which is also known as 2,5-dimethoxy-a- methylphenethylamine 2, 5-dimethoxy-a-methylphenethylamine;
(xxxi) 2,5-dimethoxy-4-(n)-propylthiophenethylamine, which is also known as 2C-T-7;
(xxxi) 2,5-dimethoxy-4-(n)-propylthiophenethylamine, which is also known -6- LB795 LB795 2026 as 2C-T-7;
(xxxiii) 4-methyl-2,5-dimethoxy-amphetamine, which is also known as 4-methyl-2,5-dimethoxy-amethylphenethylamine;
(xxxiii) 4-methyl-2,5-dimethoxy-amphetamine, which is also known as 4- methyl-2,5-dimethoxy-amethylphenethylamine;
(xxxvi) 3,4-methylenedioxy-N-ethylamphetamine, which is also known as N-ethyl-alpha-methyl-3,4(methylenedioxy)phenethylamine, MDE, MDEA;
(xxxvi) 3,4-methylenedioxy-N-ethylamphetamine, which is also known as N- ethyl-alpha-methyl-3,4(methylenedioxy)phenethylamine, MDE, MDEA;
(A) 5-methoxy-N,N-diallyltryptamine, which is also known as 5-MeO- -18- LB795 LB795 2026 DALT;
(A) 5-methoxy-N,N-diallyltryptamine, which is also known as 5-MeO-DALT;
(B) 4-acetoxy-N,N-dimethyltryptamine, which is also known as 4-AcO- DMT or OAcetylpsilocin;
(B) 4-acetoxy-N,N-dimethyltryptamine, which is also known as 4-AcO-DMT or OAcetylpsilocin;
(C) 4-hydroxy-N-methyl-N-ethyltryptamine, which is also known as 4- HO-MET;
(C) 4-hydroxy-N-methyl-N-ethyltryptamine, which is also known as 4-HO-MET;
(D) 4-hydroxy-N,N-diisopropyltryptamine, which is also known as 4- HO-DIPT;
(D) 4-hydroxy-N,N-diisopropyltryptamine, which is also known as 4-HO-DIPT;
(E) 5-methoxy-N-methyl-N-isopropyltryptamine, which is also known as 5-MeOMiPT;
(E) 5-methoxy-N-methyl-N-isopropyltryptamine, which is also known as 5- MeOMiPT;
(F) 5-Methoxy-N,N-Dimethyltryptamine, which is also known as 5-MeO- DMT;
(F) 5-Methoxy-N,N-Dimethyltryptamine, which is also known as 5-MeO-DMT;
(G) 5-methoxy-N,N-diisopropyltryptamine, which is also known as 5- MeO-DiPT;
(G) 5-methoxy-N,N-diisopropyltryptamine, which is also known as 5-MeO- DiPT;
or (B) Unless listed in another schedule, any substance which contains any quantity of any material, compound, mixture, or structure, other than bupropion, that is structurally derived by any means from 2- aminopropan-1-one by substitution at the 1-position with either phenyl, naphthyl, or thiophene ring systems, whether or not the compound is -19- LB795 LB795 2026 further modified in any of the following ways:
or (B) Unless listed in another schedule, any substance which contains any quantity of any material, compound, mixture, or structure, other than bupropion, that is structurally derived by any means from 2-aminopropan-1-one by substitution at the 1-position with either phenyl, naphthyl, or thiophene ring systems, whether or not the compound is further modified in any of the following ways:
-20- LB795 LB795 2026 (2) N-ethylamphetamine;
(2) N-ethylamphetamine;
or 4,5- dihydro-5-phenyl-2-oxazolamine;
or 4,5-dihydro-5- phenyl-2-oxazolamine;
alpha- aminopropiophenone;
alpha-aminopropiophenone;
2-aminopropiophenone;
2- aminopropiophenone;
alpha- (methylamino)propiophenone;
alpha- -7- LB795 LB795 2026 (methylamino)propiophenone;
alpha- N-methylaminopropiophenone;
alpha-N- methylaminopropiophenone;
N-methylcathinone;
N- methylcathinone;
(10) N-phenyl-N' -(3-(1- phenylpropan-2-yl)-1,2,3-oxadiazol-3- ium-5-yl)carbamimidate), including its salts, isomers, and salts of isomers;
(10) N-phenyl-N' -(3-(1- phenylpropan-2-yl)-1,2,3-oxadiazol-3- ium-5- yl)carbamimidate), including its salts, isomers, and salts of isomers;
(11) Mesocarb (N-phenyl-N'-(3-(1-phenylpropan-2-yl)-1,2,3- oxadiazol-3-ium-5-yl)carbamimidate);
(11) Mesocarb (N-phenyl-N'-(3-(1-phenylpropan-2-yl)-1,2,3-oxadiazol-3- ium-5-yl)carbamimidate);
-21- LB795 LB795 2026 (1) Opium and opiate, and any salt, compound, derivative, or preparation of opium or opiate, excluding apomorphine, buprenorphine, thebaine-derived butorphanol, dextrorphan, nalbuphine, nalmefene, naloxone, and naltrexone and their salts, but including the following:
(1) Opium and opiate, and any salt, compound, derivative, or preparation of opium or opiate, excluding apomorphine, buprenorphine, thebaine-derived butorphanol, dextrorphan, nalbuphine, nalmefene, naloxone, and naltrexone and their salts, but including the following:
(4) Coca leaves and any salt, compound, derivative, or preparation of coca leaves, and any salt, compound, derivative, or preparation thereof which is chemically equivalent to or identical with any of these substances, including cocaine or ecgonine and its salts, optical isomers, -22- LB795 LB795 2026 and salts of optical isomers, except that the substances shall not include decocainized coca leaves or extractions which do not contain cocaine or ecgonine;
(4) Coca leaves and any salt, compound, derivative, or preparation of coca leaves, and any salt, compound, derivative, or preparation thereof which is chemically equivalent to or identical with any of these substances, including cocaine or ecgonine and its salts, optical isomers, and salts of optical isomers, except that the substances shall not include decocainized coca leaves or extractions which do not contain cocaine or ecgonine;
(12) Moramide-intermediate, 2-methyl-3-morpholino-1,1- diphenylpropane-carboxylic acid;
(12) Moramide-intermediate, 2-methyl-3-morpholino-1,1-diphenylpropane- carboxylic acid;
(17) Pethidine-Intermediate-B, ethyl-4-phenylpiperidine-4- carboxylate;
(17) Pethidine-Intermediate-B, ethyl-4-phenylpiperidine-4-carboxylate;
-23- LB795 LB795 2026 (18) Pethidine-Intermediate-C, 1-methyl-4-phenylpiperidine-4- carboxylic acid;
(18) Pethidine-Intermediate-C, 1-methyl-4-phenylpiperidine-4-carboxylic acid;
(19) Phenazocine;
-8- LB795 LB795 2026 (19) Phenazocine;
-24- LB795 LB795 2026 (1) Amobarbital;
(1) Amobarbital;
Phenyl-2-propanone;
Phenyl-2- propanone;
Schedule III (a) Any material, compound, mixture, or preparation which contains any quantity of the following substances having a potential for abuse associated with a stimulant effect on the central nervous system, including their salts, isomers, whether optical, position, or geometric, -25- LB795 LB795 2026 and salts of such isomers whenever the existence of such salts, isomers, and salts of isomers is possible within the specific chemical designation:
Schedule III (a) Any material, compound, mixture, or preparation which contains any quantity of the following substances having a potential for abuse associated with a stimulant effect on the central nervous system, including their salts, isomers, whether optical, position, or geometric, and salts of such isomers whenever the existence of such salts, isomers, and salts of isomers is possible within the specific chemical designation:
(15) Sulfonethylmethane;
-9- LB795 LB795 2026 (15) Sulfonethylmethane;
-26- LB795 LB795 2026 (19) Thiamylal;
(19) Thiamylal;
(+/-)-2-(2-chlorophenyl)-2-(methylamino)- cyclohexanone;
(+/-)-2-(2-chlorophenyl)-2-(methylamino)-cyclohexanone;
2-(ethylamino)-2-(2-thienyl)- cyclohexanone.
2-(ethylamino)-2-(2-thienyl)-cyclohexanone.
4-(2-fluorophenyl)-6,8-dihydro-1,3,8- trimethylpyrazolo-(3,4-e) (1,4)-diazepin-7(1H)-one, and flupyrazapon;
4-(2- fluorophenyl)-6,8-dihydro-1,3,8-trimethylpyrazolo-(3,4-e) (1,4)-diazepin-7(1H)- one, and flupyrazapon;
-27- LB795 LB795 2026 (iv) Xylazine-M (HO-2,6-dimethylaniline isomer 1);
(iv) Xylazine-M (HO-2,6-dimethylaniline isomer 1);
(iv) The manufacturing, distribution, or use of a xylazine bulk -28- LB795 LB795 2026 chemical for pharmaceutical compounding by licensed pharmacists or veterinarians for a nonhuman species in accordance with subdivision (B) (i) or (ii) of this subdivision (27);
(iv) The manufacturing, distribution, or use of a xylazine bulk chemical for pharmaceutical compounding by licensed pharmacists or veterinarians for a nonhuman species in accordance with subdivision (B)(i) or (ii) of this subdivision (27);
(D) Not more than three hundred milligrams of ethylmorphine per one hundred milliliters or not more than fifteen milligrams per dosage unit, with one or more active, nonnarcotic ingredients in recognized therapeutic amounts;
(D) Not more than three hundred milligrams of ethylmorphine per one -10- LB795 LB795 2026 hundred milliliters or not more than fifteen milligrams per dosage unit, with one or more active, nonnarcotic ingredients in recognized therapeutic amounts;
(E) Not more than five hundred milligrams of opium per one hundred milliliters or per one hundred grams, or not more than twenty-five milligrams per dosage unit, with one or more active, nonnarcotic -29- LB795 LB795 2026 ingredients in recognized therapeutic amounts;
(E) Not more than five hundred milligrams of opium per one hundred milliliters or per one hundred grams, or not more than twenty-five milligrams per dosage unit, with one or more active, nonnarcotic ingredients in recognized therapeutic amounts;
(4) 1-androstenediol (3-beta,17-beta-dihydroxy-5-alpha-androst-1- ene);
(4) 1-androstenediol (3-beta,17-beta-dihydroxy-5-alpha-androst-1-ene);
(5) 1-androstenediol (3-alpha,17-beta-dihydroxy-5-alpha-androst-1- ene);
(5) 1-androstenediol (3-alpha,17-beta-dihydroxy-5-alpha-androst-1-ene);
(11) Bolasterone (7-alpha,17-alpha-dimethyl-17-beta- hydroxyandrost-4-en-3-one);
(11) Bolasterone (7-alpha,17-alpha-dimethyl-17-beta-hydroxyandrost-4-en-3- one);
(14) Calusterone (7-beta,17-alpha-dimethyl-17-beta-hydroxyandrost-4- -30- LB795 LB795 2026 en-3-one);
(14) Calusterone (7-beta,17-alpha-dimethyl-17-beta-hydroxyandrost-4-en-3- one);
(16) Dehydrochloromethyltestosterone (4-chloro-17-beta-hydroxy-17- alpha-methyl-androst-1,4-dien-3-one);
(16) Dehydrochloromethyltestosterone (4-chloro-17-beta-hydroxy-17-alpha- methyl-androst-1,4-dien-3-one);
(17) Desoxymethyltestosterone (17-alpha-methyl-5-alpha-androst-2- en-17-beta-ol) (a.k.a.
(17) Desoxymethyltestosterone (17-alpha-methyl-5-alpha-androst-2-en-17- beta-ol) (a.k.a.
(20) Drostanolone (17-beta-hydroxy-2-alpha-methyl-5-alpha- androstan-3-one);
(20) Drostanolone (17-beta-hydroxy-2-alpha-methyl-5-alpha-androstan-3- one);
(2-formyl-17-alpha-methyl-11- alpha,17-beta-dihydroxyandrost-1,4-dien-3-one);
(2-formyl-17-alpha-methyl-11-alpha,17- beta-dihydroxyandrost-1,4-dien-3-one);
(24) Furazabol (17-alpha-methyl-17-beta-hydroxyandrostano[2,3-c]- furazan);
(24) Furazabol (17-alpha-methyl-17-beta-hydroxyandrostano[2,3-c]-furazan);
(27) 4-hydroxy-19-nortestosterone (4,17-beta-dihydroxy-estr-4-en-3- one);
(27) 4-hydroxy-19-nortestosterone (4,17-beta-dihydroxy-estr-4-en-3-one);
(28) Mestanolone (17-alpha-methyl-17-beta-hydroxy-5-androstan-3- one);
(28) Mestanolone (17-alpha-methyl-17-beta-hydroxy-5-androstan-3-one);
(29) Mesterolone (17-alpha-methyl-17-beta-hydroxy-5-androstan-3- one);
(29) Mesterolone (17-alpha-methyl-17-beta-hydroxy-5-androstan-3-one);
(30) Methandienone (17-alpha-methyl-17-beta-hydroxyandrost-1,4- dien-3-one);
(30) Methandienone (17-alpha-methyl-17-beta-hydroxyandrost-1,4-dien-3- one);
(31) Methandriol (17-alpha-methyl-3-beta,17-beta-dihydroxyandrost-5- ene);
(31) Methandriol (17-alpha-methyl-3-beta,17-beta-dihydroxyandrost-5-ene);
(32) Methasterone (2-alpha,17-alpha-dimethyl-5-alpha-androstan-17- -31- LB795 LB795 2026 beta-ol-3-one);
(32) Methasterone (2-alpha,17-alpha-dimethyl-5-alpha-androstan-17-beta- ol-3-one);
(33) Methenolone (1-methyl-17-beta-hydroxy-5-alpha-androst-1-en-3- one);
(33) Methenolone (1-methyl-17-beta-hydroxy-5-alpha-androst-1-en-3-one);
(37) 17-alpha-methyl-4-hydroxynandrolone (17-alpha-methyl-4- hydroxy-17-beta-hydroxyestr-4-en-3-one);
(37) 17-alpha-methyl-4-hydroxynandrolone (17-alpha-methyl-4-hydroxy-17- beta-hydroxyestr-4-en-3-one);
(38) Methyldienolone (17-alpha-methyl-17-beta-hydroxyestra-4,9(10)- dien-3-one);
(38) Methyldienolone (17-alpha-methyl-17-beta-hydroxyestra-4,9(10)-dien-3- one);
(40) Methyltestosterone (17-alpha-methyl-17-beta-hydroxyandrost-4- en-3-one);
(40) Methyltestosterone (17-alpha-methyl-17-beta-hydroxyandrost-4-en-3- one);
(41) Mibolerone (7-alpha,17-alpha-dimethyl-17-beta-hydroxyestr-4- en-3-one);
(41) Mibolerone (7-alpha,17-alpha-dimethyl-17-beta-hydroxyestr-4-en-3- one);
(42) 17-alpha-methyl-delta-1-dihydrotestosterone (17-beta- hydroxy-17-alpha-methyl-5-alpha-androst-1-en-3-one) (a.k.a.
(42) 17-alpha-methyl-delta-1-dihydrotestosterone (17-beta-hydroxy-17- alpha-methyl-5-alpha-androst-1-en-3-one) (a.k.a.
'17-alpha- methyl-1-testosterone');
'17-alpha-methyl-1- testosterone');
(48) 19-nor-4,9(10)-androstadienedione (estra-4,9(10)-diene-3,17- dione);
-11- LB795 LB795 2026 (48) 19-nor-4,9(10)-androstadienedione (estra-4,9(10)-diene-3,17-dione);
(51) Norbolethone (13-beta, 17-alpha-diethyl-17-beta-hydroxygon-4- en-3-one);
(51) Norbolethone (13-beta, 17-alpha-diethyl-17-beta-hydroxygon-4-en-3- one);
-32- LB795 LB795 2026 (53) Norethandrolone (17-alpha-ethyl-17-beta-hydroxyestr-4-en-3- one);
(53) Norethandrolone (17-alpha-ethyl-17-beta-hydroxyestr-4-en-3-one);
(54) Normethandrolone (17-alpha-methyl-17-beta-hydroxyestr-4-en-3- one);
(54) Normethandrolone (17-alpha-methyl-17-beta-hydroxyestr-4-en-3-one);
(56) Oxymesterone (17-alpha-methyl-4,17-beta-dihydroxyandrost-4- en-3-one);
(56) Oxymesterone (17-alpha-methyl-4,17-beta-dihydroxyandrost-4-en-3-one);
(57) Oxymetholone (17-alpha-methyl-2-hydroxymethylene-17-beta- hydroxy-[5-alpha]-androstan-3-one);
(57) Oxymetholone (17-alpha-methyl-2-hydroxymethylene-17-beta-hydroxy-[5- alpha]-androstan-3-one);
(58) Prostanozol (17-beta-hydroxy-5-alpha-androstano[3,2- c]pyrazole);
(58) Prostanozol (17-beta-hydroxy-5-alpha-androstano[3,2-c]pyrazole);
(59) Stanozolol (17-alpha-methyl-17-beta-hydroxy-[5-alpha]- androst-2-eno[3,2-c]-pyrazole);
(59) Stanozolol (17-alpha-methyl-17-beta-hydroxy-[5-alpha]-androst-2- eno[3,2-c]-pyrazole);
(60) Stenbolone (17-beta-hydroxy-2-methyl-[5-alpha]-androst-1-en-3- one);
(60) Stenbolone (17-beta-hydroxy-2-methyl-[5-alpha]-androst-1-en-3-one);
(61) Testolactone (13-hydroxy-3-oxo-13,17-secoandrosta-1,4-dien-17- oic acid lactone);
(61) Testolactone (13-hydroxy-3-oxo-13,17-secoandrosta-1,4-dien-17-oic acid lactone);
(73) 2 alpha, 3 alpha-epithio-17 alpha-methyl-5 alpha-androstan-17 -33- LB795 LB795 2026 beta-ol;
(73) 2 alpha, 3 alpha-epithio-17 alpha-methyl-5 alpha-androstan-17 beta- ol;
(75) 4-chloro-17 alpha-methyl-17 beta-hydroxy-androst-4-en-3,11- dione;
(75) 4-chloro-17 alpha-methyl-17 beta-hydroxy-androst-4-en-3,11-dione;
Some other names for dronabinol are (6aR- trans)-6a,7,8,10a-tetrahydro-6,6,9-trimethyl-3-pentyl-6H-dibenzo (b,d)pyran-1-ol or (-)-delta-9-(trans)-tetrahydrocannabinol.
Some other names for dronabinol are (6aR-trans)-6a,7,8,10a- tetrahydro-6,6,9-trimethyl-3-pentyl-6H-dibenzo (b,d)pyran-1-ol or (-)-delta-9- (trans)-tetrahydrocannabinol.
(4) Chlordiazepoxide, but not including librax (chlordiazepoxide -34- LB795 LB795 2026 hydrochloride and clindinium bromide) or menrium (chlordiazepoxide and water soluble esterified estrogens);
(4) Chlordiazepoxide, but not including librax (chlordiazepoxide hydrochloride and clindinium bromide) or menrium (chlordiazepoxide and water soluble esterified estrogens);
(25) Clotiazepam;
-12- LB795 LB795 2026 (25) Clotiazepam;
-35- LB795 LB795 2026 (34) Ketazolam;
(34) Ketazolam;
-36- LB795 LB795 2026 (b) Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances having a stimulant effect on the central nervous system, including their salts, isomers, whether optical, position, or geometric, and salts of such isomers whenever the existence of such salts, isomers, and salts of isomers is possible within the specific chemical designation:
(b) Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances having a stimulant effect on the central nervous system, including their salts, isomers, whether optical, position, or geometric, and salts of such isomers whenever the existence of such salts, isomers, and salts of isomers is possible within the specific chemical designation:
-37- LB795 LB795 2026 (d) Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances, including their salts:
(d) Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances, including their salts:
(2) The following drug products containing ephedrine, its salts, optical isomers, and salts of such optical isomers, are excepted from subdivision (f)(1) of Schedule IV if they (A) are stored behind a counter, in an area not accessible to customers, or in a locked case so that a customer needs assistance from an employee to access the drug product;
(2) The following drug products containing ephedrine, its salts, optical isomers, and salts of such optical isomers, are excepted from subdivision (f) (1) of Schedule IV if they (A) are stored behind a counter, in an area not -13- LB795 LB795 2026 accessible to customers, or in a locked case so that a customer needs assistance from an employee to access the drug product;
and -38- LB795 LB795 2026 (E) are not marketed, advertised, or represented in any manner for the indication of stimulation, mental alertness, euphoria, ecstasy, a buzz or high, heightened sexual performance, or increased muscle mass:
and (E) are not marketed, advertised, or represented in any manner for the indication of stimulation, mental alertness, euphoria, ecstasy, a buzz or high, heightened sexual performance, or increased muscle mass:
(b) Unless specifically exempted or excluded or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances having a stimulant effect on the central nervous system, including its salts, isomers, and -39- LB795 LB795 2026 salts of isomers:
(b) Unless specifically exempted or excluded or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances having a stimulant effect on the central nervous system, including its salts, isomers, and salts of isomers:
28-416 (1) Except as authorized by the Uniform Controlled Substances Act, it shall be unlawful for any person knowingly or intentionally:
28-416 (1) Except as authorized by the Uniform Controlled Substances Act, it shall be unlawful for any person knowingly or intentionally:
or (c) a controlled -40- LB795 LB795 2026 substance classified in Schedule IV or V of section 28-405 shall be guilty of a Class IIIA felony.
or (c) a controlled substance classified in Schedule IV or V of section 28-405 shall be guilty of a Class IIIA felony.
(4)(a) Except as authorized by the Uniform Controlled Substances Act, any person eighteen years of age or older who knowingly or intentionally manufactures, distributes, delivers, dispenses, or possesses with intent to manufacture, distribute, deliver, or dispense a controlled substance or a counterfeit controlled substance (i) to a person under the age of eighteen years, (ii) in, on, or within one thousand feet of the real property comprising a public or private elementary, vocational, or secondary school, a community college, a public or private college, junior college, or university, or a playground, or (iii) within one hundred feet of a public or private youth center, public swimming pool, or video arcade facility shall be punished by the next higher penalty classification than the penalty prescribed in subsection (2), (7), (8), (9), or (10), or (11) of this section, depending upon the controlled substance involved, for the first violation and for a second or subsequent violation shall be punished by the next higher penalty classification than that prescribed for a first violation of this subsection, but in no event shall such person be punished by a penalty greater than a Class IB felony.
-14- LB795 LB795 2026 (4)(a) Except as authorized by the Uniform Controlled Substances Act, any person eighteen years of age or older who knowingly or intentionally manufactures, distributes, delivers, dispenses, or possesses with intent to manufacture, distribute, deliver, or dispense a controlled substance or a counterfeit controlled substance (i) to a person under the age of eighteen years, (ii) in, on, or within one thousand feet of the real property comprising a public or private elementary, vocational, or secondary school, a community college, a public or private college, junior college, or university, or a playground, or (iii) within one hundred feet of a public or private youth center, public swimming pool, or video arcade facility shall be punished by the next higher penalty classification than the penalty prescribed in subsection (2), (7), (8), (9), or (10), or (11) of this section, depending upon the controlled substance involved, for the first violation and for a second or subsequent violation shall be punished by the next higher penalty classification than that prescribed for a first violation of this subsection, but in no event shall such person be punished by a penalty greater than a Class IB felony.
-41- LB795 LB795 2026 (i) Playground means any outdoor facility, including any parking lot appurtenant to the facility, intended for recreation, open to the public, and with any portion containing three or more apparatus intended for the recreation of children, including sliding boards, swingsets, and teeterboards;
(i) Playground means any outdoor facility, including any parking lot appurtenant to the facility, intended for recreation, open to the public, and with any portion containing three or more apparatus intended for the recreation of children, including sliding boards, swingsets, and teeterboards;
(c) Any person who violates subdivision (a) or (b) of this subsection shall be punished by the next higher penalty classification than the penalty prescribed in subsection (2), (7), (8), (9), or (10), or -42- LB795 LB795 2026 (11) of this section, depending upon the controlled substance involved, for the first violation and for a second or subsequent violation shall be punished by the next higher penalty classification than that prescribed for a first violation of this subsection, but in no event shall such person be punished by a penalty greater than a Class IB felony.
(c) Any person who violates subdivision (a) or (b) of this subsection shall be punished by the next higher penalty classification than the penalty prescribed in subsection (2), (7), (8), (9), or (10), or (11) of this section, depending upon the controlled substance involved, for the first violation and for a second or subsequent violation shall be punished by the next higher penalty classification than that prescribed for a first violation of this subsection, but in no event shall such person be punished by a penalty greater than a Class IB felony.
-43- LB795 LB795 2026 (b) At least twenty-eight grams but less than one hundred forty grams shall be guilty of a Class IC felony;
(b) At least twenty-eight grams but less than one hundred forty grams shall be guilty of a Class IC felony;
(10) Any person who violates subsection (1) of this section with respect to amphetamine, its salts, optical isomers, and salts of its isomers, or with respect to methamphetamine, its salts, optical isomers, and salts of its isomers, in a quantity of:
(10) Any person who violates subsection (1) of this section with respect to amphetamine, its salts, optical isomers, and salts of its isomers, or with respect to methamphetamine, its salts, optical isomers, and salts of its -15- LB795 LB795 2026 isomers, in a quantity of:
(12) (11) Any person knowingly or intentionally possessing marijuana weighing more than one ounce but not more than one pound shall be guilty -44- LB795 LB795 2026 of a Class III misdemeanor.
(12) (11) Any person knowingly or intentionally possessing marijuana weighing more than one ounce but not more than one pound shall be guilty of a Class III misdemeanor.
-45- LB795 LB795 2026 (i) The person knowingly or intentionally possessed a firearm while in violation of subsection (1) of this section;
(i) The person knowingly or intentionally possessed a firearm while in violation of subsection (1) of this section;
-46- LB795 LB795 2026 (ii) For a second offense, the court may, as a part of the judgment of conviction or adjudication, (A) impound any such licenses or permits for ninety days and (B) require such person to complete no fewer than twenty and no more than forty hours of community service and to attend a drug education class;
(ii) For a second offense, the court may, as a part of the judgment of conviction or adjudication, (A) impound any such licenses or permits for ninety -16- LB795 LB795 2026 days and (B) require such person to complete no fewer than twenty and no more than forty hours of community service and to attend a drug education class;
and (iii) For a third or subsequent offense, the court may, as part of the judgment of conviction or adjudication, (A) prohibit such person from obtaining any permit or any license pursuant to the act for which such person would otherwise be eligible until twelve months after the date of such order and (B) require such person to complete no fewer than sixty -47- LB795 LB795 2026 hours of community service, to attend a drug education class, and to submit to a drug assessment by a licensed alcohol and drug counselor.
and (iii) For a third or subsequent offense, the court may, as part of the judgment of conviction or adjudication, (A) prohibit such person from obtaining any permit or any license pursuant to the act for which such person would otherwise be eligible until twelve months after the date of such order and (B) require such person to complete no fewer than sixty hours of community service, to attend a drug education class, and to submit to a drug assessment by a licensed alcohol and drug counselor.
(4) Prosecutor includes the Attorney General of the State of Nebraska, the deputy attorney general, assistant attorneys general, a county attorney, a deputy county attorney, or any person so designated by the Attorney General, a county attorney, or a court of the state to carry -48- LB795 LB795 2026 out the powers conferred by the act;
(4) Prosecutor includes the Attorney General of the State of Nebraska, the deputy attorney general, assistant attorneys general, a county attorney, a deputy county attorney, or any person so designated by the Attorney General, a county attorney, or a court of the state to carry out the powers conferred by the act;
Arson in the first degree under section 28-502;
Arson in the first degree -17- LB795 LB795 2026 under section 28-502;
arson in the second degree under section -49- LB795 LB795 2026 28-503;
arson in the second degree under section 28-503;
-50- LB795 LB795 2026 (e) Offenses involving governmental operations which include:
(e) Offenses involving governmental operations which include:
possession of a deadly -51- LB795 LB795 2026 weapon by a prohibited person under section 28-1206;
possession of a deadly weapon by a prohibited person under section 28-1206;
and (k) A violation of the Computer Crimes Act;
and -18- LB795 LB795 2026 (k) A violation of the Computer Crimes Act;
-52- LB795 LB795 2026 (a) Incurred or contracted in gambling activity which was in violation of federal law or the law of the state or which is unenforceable under state or federal law in whole or in part as to principal or interest because of the laws relating to usury;
(a) Incurred or contracted in gambling activity which was in violation of federal law or the law of the state or which is unenforceable under state or federal law in whole or in part as to principal or interest because of the laws relating to usury;
-53- LB795 LB795 2026 (i) A violation of subsection (3) or (14) (13) of section 28-416 or of section 28-441;
(i) A violation of subsection (3) or (14) (13) of section 28-416 or of section 28-441;
-54-
-19-
⬇ Download PDF
View plain text versions (4)

Action History

  1. Provisions/portions of LB817 amended into LB795 by AM2092

  2. Presented to Governor on February 27, 2026

  3. Approved by Governor on March 3, 2026

  4. Conrad MO423 failed

  5. Motion to return to Select File withdrawn

  6. Conrad FA977 not considered

  7. Conrad FA978 withdrawn

  8. Conrad FA979 withdrawn

  9. Conrad FA981 withdrawn

  10. Conrad FA982 withdrawn

  11. Dispensing of reading at large approved

  12. Passed on Final Reading 32-14-3

  13. President/Speaker signed

  14. Placed on Final Reading with ST55

  15. Enrollment and Review ST55 filed

  16. Enrollment and Review ST55 recorded

  17. DeKay MO434 Invoke cloture pursuant to Rule 7, Sec. 10 filed

  18. DeKay MO434 prevailed

  19. Conrad FA980 lost

  20. Storer AM2092 adopted

  21. Advanced to Enrollment and Review for Engrossment

  22. Dungan MO412 not considered

  23. Dungan MO413 not considered

  24. Dungan MO421 failed

  25. McKinney MO415 failed

  26. Dungan MO422 Reconsider the vote taken on MO415 filed

  27. Dungan MO422 failed

  28. Kauth FA424 withdrawn

  29. Storer AM2092 pending

  30. Conrad FA980 filed

  31. Conrad FA980 pending

  32. Conrad MO423 Recommit to the Judiciary Committee filed

  33. Conrad FA977 filed

  34. Conrad FA978 filed

  35. Conrad FA979 filed

  36. Conrad FA981 filed

  37. Conrad FA982 filed

  38. McKinney MO414 failed

  39. Dungan MO421 Reconsider the vote taken on MO414 filed

  40. Dungan MO421 pending

  41. Storer AM2092 filed

  42. Dungan MO412 Bracket filed

  43. Dungan MO413 Indefinitely postpone filed

  44. McKinney MO414 Bracket until April 17, 2026 filed

  45. McKinney MO415 Recommit to the Judiciary Committee filed

  46. Placed on Select File

  47. Advanced to Enrollment and Review Initial

  48. Placed on General File

  49. Notice of hearing for January 22, 2026

  50. Referred to Judiciary Committee

  51. Kauth FA424 filed

  52. Date of introduction

Sponsors

Sponsorship breakdown

Export CSV (upgrade) →

1 sponsors · 0 co-sponsors · 48 not signed on · 54 voted No

Sponsors (1)

Co-sponsors (0)

None.

Not signed on (48)

48 members have not signed on to this bill.

Show all 48 →

"Not signed on" means a member has not sponsored or co-sponsored this bill — it does not imply opposition. Members flagged Voted No have a recorded No vote on this bill.

Whip count is in markup. Polling the chamber and every recorded vote this session. Only the first open is slow. It’s instant for you after this. Calling the roll · Tallying · Engrossing

Votes

Passed on Final Reading 32-14-3

Passed 32 Yea · 14 Nay · 3 Other
Party YeaNayPresentNot Voting
Unaffiliated 321403
Total 321403
% of votes cast 65%29%0%6%
How each member voted (49)
Member Party Vote
Ashlei Spivey — Nay
Barry DeKay — Yea
Beau Ballard — Yea
Ben Hansen — Yea
Bob Andersen — Yea
Bob Hallstrom — Yea
Brian Hardin — Yea
Carolyn Bosn — Yea
Christy Armendariz — Not Voting
Dan Lonowski — Yea
Dan Quick — Nay
Danielle Conrad — Nay
Dave Murman — Yea
Dave Wordekemper — Yea
Dunixi Guereca — Nay
Eliot Bostar — Yea
Fred Meyer — Yea
George Dungan — Nay
Glen Meyer — Yea
Jana Hughes — Yea
Jane Raybould — Nay
Jared Storm — Yea
Jason Prokop — Yea
John Arch — Yea
John Cavanaugh — Nay
John Fredrickson — Nay
Kathleen Kauth — Yea
Loren Lippincott — Yea
Machaela Cavanaugh — Nay
Margo Juarez — Nay
Megan Hunt — Nay
Merv Riepe — Yea
Mike Jacobson — Yea
Mike Moser — Not Voting
Myron Dorn — Yea
Paul Strommen — Yea
R. Brad von Gillern — Yea
Rick Holdcroft — Yea
Rita Sanders — Yea
Robert Clements — Yea
Robert Dover — Not Voting
Stan Clouse — Yea
Tanya Storer — Yea
Teresa Ibach — Yea
Terrell McKinney — Nay
Tom Brandt — Yea
Tony Sorrentino — Yea
Victor Rountree — Nay
Wendy DeBoer — Nay

Official roll call →

Conrad MO423 failed

Failed 12 Yea · 29 Nay · 8 Other
Party YeaNayPresentNot Voting
Unaffiliated 122908
Total 122908
% of votes cast 24%59%0%16%
How each member voted (49)
Member Party Vote
Ashlei Spivey — Yea
Barry DeKay — Nay
Beau Ballard — Nay
Ben Hansen — Nay
Bob Andersen — Nay
Bob Hallstrom — Nay
Brian Hardin — Nay
Carolyn Bosn — Nay
Christy Armendariz — Not Voting
Dan Lonowski — Nay
Dan Quick — Not Voting
Danielle Conrad — Yea
Dave Murman — Nay
Dave Wordekemper — Nay
Dunixi Guereca — Not Voting
Eliot Bostar — Nay
Fred Meyer — Yea
George Dungan — Yea
Glen Meyer — Nay
Jana Hughes — Nay
Jane Raybould — Not Voting
Jared Storm — Nay
Jason Prokop — Nay
John Arch — Nay
John Cavanaugh — Yea
John Fredrickson — Yea
Kathleen Kauth — Nay
Loren Lippincott — Nay
Machaela Cavanaugh — Yea
Margo Juarez — Yea
Megan Hunt — Yea
Merv Riepe — Not Voting
Mike Jacobson — Not Voting
Mike Moser — Not Voting
Myron Dorn — Nay
Paul Strommen — Nay
R. Brad von Gillern — Nay
Rick Holdcroft — Nay
Rita Sanders — Nay
Robert Clements — Nay
Robert Dover — Not Voting
Stan Clouse — Nay
Tanya Storer — Nay
Teresa Ibach — Nay
Terrell McKinney — Yea
Tom Brandt — Nay
Tony Sorrentino — Nay
Victor Rountree — Yea
Wendy DeBoer — Yea

Official roll call →

DeKay MO434 prevailed

Failed 35 Yea · 13 Nay · 1 Other
Party YeaNayPresentNot Voting
Unaffiliated 351301
Total 351301
% of votes cast 71%27%0%2%
How each member voted (49)
Member Party Vote
Ashlei Spivey — Nay
Barry DeKay — Yea
Beau Ballard — Yea
Ben Hansen — Yea
Bob Andersen — Yea
Bob Hallstrom — Yea
Brian Hardin — Yea
Carolyn Bosn — Yea
Cavanaugh, J. — Nay
Cavanaugh, M. — Nay
Christy Armendariz — Yea
Dan Lonowski — Yea
Dan Quick — Nay
Danielle Conrad — Nay
Dave Murman — Yea
Dave Wordekemper — Yea
Dunixi Guereca — Nay
Eliot Bostar — Yea
George Dungan — Nay
Jana Hughes — Yea
Jane Raybould — Not Voting
Jared Storm — Yea
Jason Prokop — Yea
John Arch — Yea
John Fredrickson — Nay
Kathleen Kauth — Yea
Loren Lippincott — Yea
Margo Juarez — Nay
Megan Hunt — Nay
Merv Riepe — Yea
Meyer, F. — Yea
Meyer, G. — Yea
Mike Jacobson — Yea
Mike Moser — Yea
Myron Dorn — Yea
Paul Strommen — Yea
Rick Holdcroft — Yea
Rita Sanders — Yea
Robert Clements — Yea
Robert Dover — Yea
Stan Clouse — Yea
Tanya Storer — Yea
Teresa Ibach — Yea
Terrell McKinney — Nay
Tom Brandt — Yea
Tony Sorrentino — Yea
Victor Rountree — Nay
Wendy DeBoer — Nay
von Gillern — Yea

Official roll call →

Conrad FA980 lost

Failed 13 Yea · 34 Nay · 2 Other
Party YeaNayPresentNot Voting
Unaffiliated 133402
Total 133402
% of votes cast 27%69%0%4%
How each member voted (49)
Member Party Vote
Ashlei Spivey — Yea
Barry DeKay — Nay
Beau Ballard — Nay
Bob Andersen — Nay
Bob Hallstrom — Nay
Brian Hardin — Nay
Carolyn Bosn — Nay
Cavanaugh, J. — Yea
Cavanaugh, M. — Yea
Christy Armendariz — Nay
Dan Lonowski — Nay
Dan Quick — Yea
Danielle Conrad — Yea
Dave Murman — Nay
Dave Wordekemper — Nay
Dunixi Guereca — Yea
Eliot Bostar — Not Voting
George Dungan — Yea
Hansen, B. — Nay
Jana Hughes — Nay
Jane Raybould — Yea
Jared Storm — Nay
Jason Prokop — Not Voting
John Arch — Nay
John Fredrickson — Nay
Kathleen Kauth — Nay
Loren Lippincott — Nay
Margo Juarez — Yea
Megan Hunt — Yea
Merv Riepe — Nay
Meyer, F. — Nay
Meyer, G. — Nay
Mike Jacobson — Nay
Mike Moser — Nay
Myron Dorn — Nay
Paul Strommen — Nay
Rick Holdcroft — Nay
Rita Sanders — Nay
Robert Clements — Nay
Robert Dover — Nay
Stan Clouse — Nay
Tanya Storer — Nay
Teresa Ibach — Nay
Terrell McKinney — Yea
Tom Brandt — Nay
Tony Sorrentino — Nay
Victor Rountree — Yea
Wendy DeBoer — Yea
von Gillern — Nay

Official roll call →

Advanced to Enrollment and Review for Engrossment

Passed 35 Yea · 14 Nay
Party YeaNayPresentNot Voting
Unaffiliated 351400
Total 351400
% of votes cast 71%29%0%0%
How each member voted (49)
Member Party Vote
Ashlei Spivey — Nay
Barry DeKay — Yea
Beau Ballard — Yea
Ben Hansen — Yea
Bob Andersen — Yea
Bob Hallstrom — Yea
Brian Hardin — Yea
Carolyn Bosn — Yea
Christy Armendariz — Yea
Dan Lonowski — Yea
Dan Quick — Nay
Danielle Conrad — Nay
Dave Murman — Yea
Dave Wordekemper — Yea
Dunixi Guereca — Nay
Eliot Bostar — Yea
Fred Meyer — Yea
George Dungan — Nay
Glen Meyer — Yea
Jana Hughes — Yea
Jane Raybould — Nay
Jared Storm — Yea
Jason Prokop — Yea
John Arch — Yea
John Cavanaugh — Nay
John Fredrickson — Nay
Kathleen Kauth — Yea
Loren Lippincott — Yea
Machaela Cavanaugh — Nay
Margo Juarez — Nay
Megan Hunt — Nay
Merv Riepe — Yea
Mike Jacobson — Yea
Mike Moser — Yea
Myron Dorn — Yea
Paul Strommen — Yea
R. Brad von Gillern — Yea
Rick Holdcroft — Yea
Rita Sanders — Yea
Robert Clements — Yea
Robert Dover — Yea
Stan Clouse — Yea
Tanya Storer — Yea
Teresa Ibach — Yea
Terrell McKinney — Nay
Tom Brandt — Yea
Tony Sorrentino — Yea
Victor Rountree — Nay
Wendy DeBoer — Nay

Official roll call →

Storer AM2092 adopted

Failed 36 Yea · 13 Nay
Party YeaNayPresentNot Voting
Unaffiliated 361300
Total 361300
% of votes cast 73%27%0%0%
How each member voted (49)
Member Party Vote
Ashlei Spivey — Nay
Barry DeKay — Yea
Beau Ballard — Yea
Ben Hansen — Yea
Bob Andersen — Yea
Bob Hallstrom — Yea
Brian Hardin — Yea
Carolyn Bosn — Yea
Christy Armendariz — Yea
Dan Lonowski — Yea
Dan Quick — Nay
Danielle Conrad — Nay
Dave Murman — Yea
Dave Wordekemper — Yea
Dunixi Guereca — Nay
Eliot Bostar — Yea
Fred Meyer — Yea
George Dungan — Nay
Glen Meyer — Yea
Jana Hughes — Yea
Jane Raybould — Yea
Jared Storm — Yea
Jason Prokop — Yea
John Arch — Yea
John Cavanaugh — Nay
John Fredrickson — Nay
Kathleen Kauth — Yea
Loren Lippincott — Yea
Machaela Cavanaugh — Nay
Margo Juarez — Nay
Megan Hunt — Nay
Merv Riepe — Yea
Mike Jacobson — Yea
Mike Moser — Yea
Myron Dorn — Yea
Paul Strommen — Yea
R. Brad von Gillern — Yea
Rick Holdcroft — Yea
Rita Sanders — Yea
Robert Clements — Yea
Robert Dover — Yea
Stan Clouse — Yea
Tanya Storer — Yea
Teresa Ibach — Yea
Terrell McKinney — Nay
Tom Brandt — Yea
Tony Sorrentino — Yea
Victor Rountree — Nay
Wendy DeBoer — Nay

Official roll call →

McKinney MO415 failed

Failed 9 Yea · 31 Nay · 9 Other
Party YeaNayPresentNot Voting
Unaffiliated 93109
Total 93109
% of votes cast 18%63%0%18%
How each member voted (49)
Member Party Vote
Ashlei Spivey — Yea
Barry DeKay — Nay
Beau Ballard — Nay
Ben Hansen — Nay
Bob Andersen — Nay
Bob Hallstrom — Nay
Brian Hardin — Nay
Carolyn Bosn — Nay
Christy Armendariz — Nay
Dan Lonowski — Nay
Dan Quick — Not Voting
Danielle Conrad — Yea
Dave Murman — Nay
Dave Wordekemper — Nay
Dunixi Guereca — Yea
Eliot Bostar — Not Voting
Fred Meyer — Nay
George Dungan — Not Voting
Glen Meyer — Nay
Jana Hughes — Nay
Jane Raybould — Not Voting
Jared Storm — Nay
Jason Prokop — Not Voting
John Arch — Nay
John Cavanaugh — Yea
John Fredrickson — Not Voting
Kathleen Kauth — Nay
Loren Lippincott — Nay
Machaela Cavanaugh — Yea
Margo Juarez — Not Voting
Megan Hunt — Yea
Merv Riepe — Nay
Mike Jacobson — Nay
Mike Moser — Not Voting
Myron Dorn — Nay
Paul Strommen — Nay
R. Brad von Gillern — Nay
Rick Holdcroft — Nay
Rita Sanders — Nay
Robert Clements — Nay
Robert Dover — Not Voting
Stan Clouse — Nay
Tanya Storer — Nay
Teresa Ibach — Nay
Terrell McKinney — Yea
Tom Brandt — Nay
Tony Sorrentino — Nay
Victor Rountree — Yea
Wendy DeBoer — Yea

Official roll call →

Dungan MO422 failed

Failed 13 Yea · 28 Nay · 8 Other
Party YeaNayPresentNot Voting
Unaffiliated 132808
Total 132808
% of votes cast 27%57%0%16%
How each member voted (49)
Member Party Vote
Ashlei Spivey — Yea
Barry DeKay — Nay
Beau Ballard — Nay
Ben Hansen — Nay
Bob Andersen — Nay
Bob Hallstrom — Nay
Brian Hardin — Nay
Carolyn Bosn — Nay
Christy Armendariz — Nay
Dan Lonowski — Nay
Dan Quick — Yea
Danielle Conrad — Yea
Dave Murman — Nay
Dave Wordekemper — Nay
Dunixi Guereca — Yea
Eliot Bostar — Not Voting
Fred Meyer — Nay
George Dungan — Yea
Glen Meyer — Nay
Jana Hughes — Nay
Jane Raybould — Not Voting
Jared Storm — Nay
Jason Prokop — Not Voting
John Arch — Nay
John Cavanaugh — Yea
John Fredrickson — Yea
Kathleen Kauth — Nay
Loren Lippincott — Nay
Machaela Cavanaugh — Yea
Margo Juarez — Yea
Megan Hunt — Yea
Merv Riepe — Not Voting
Mike Jacobson — Nay
Mike Moser — Not Voting
Myron Dorn — Not Voting
Paul Strommen — Nay
R. Brad von Gillern — Nay
Rick Holdcroft — Nay
Rita Sanders — Nay
Robert Clements — Nay
Robert Dover — Not Voting
Stan Clouse — Nay
Tanya Storer — Nay
Teresa Ibach — Nay
Terrell McKinney — Yea
Tom Brandt — Not Voting
Tony Sorrentino — Nay
Victor Rountree — Yea
Wendy DeBoer — Yea

Official roll call →

Dungan MO421 failed

Failed 12 Yea · 31 Nay · 6 Other
Party YeaNayPresentNot Voting
Unaffiliated 123106
Total 123106
% of votes cast 24%63%0%12%
How each member voted (49)
Member Party Vote
Ashlei Spivey — Yea
Barry DeKay — Nay
Beau Ballard — Nay
Ben Hansen — Nay
Bob Andersen — Nay
Bob Hallstrom — Nay
Brian Hardin — Nay
Carolyn Bosn — Nay
Christy Armendariz — Nay
Dan Lonowski — Nay
Dan Quick — Yea
Danielle Conrad — Yea
Dave Murman — Nay
Dave Wordekemper — Nay
Dunixi Guereca — Yea
Eliot Bostar — Not Voting
Fred Meyer — Nay
George Dungan — Yea
Glen Meyer — Nay
Jana Hughes — Nay
Jane Raybould — Not Voting
Jared Storm — Nay
Jason Prokop — Not Voting
John Arch — Nay
John Cavanaugh — Yea
John Fredrickson — Yea
Kathleen Kauth — Nay
Loren Lippincott — Nay
Machaela Cavanaugh — Yea
Margo Juarez — Not Voting
Megan Hunt — Yea
Merv Riepe — Nay
Mike Jacobson — Nay
Mike Moser — Not Voting
Myron Dorn — Nay
Paul Strommen — Nay
R. Brad von Gillern — Nay
Rick Holdcroft — Nay
Rita Sanders — Nay
Robert Clements — Nay
Robert Dover — Not Voting
Stan Clouse — Nay
Tanya Storer — Nay
Teresa Ibach — Nay
Terrell McKinney — Yea
Tom Brandt — Nay
Tony Sorrentino — Nay
Victor Rountree — Yea
Wendy DeBoer — Yea

Official roll call →

McKinney MO414 failed

Failed 7 Yea · 33 Nay · 9 Other
Party YeaNayPresentNot Voting
Unaffiliated 73309
Total 73309
% of votes cast 14%67%0%18%
How each member voted (49)
Member Party Vote
Ashlei Spivey — Yea
Barry DeKay — Nay
Beau Ballard — Nay
Bob Andersen — Nay
Bob Hallstrom — Nay
Brian Hardin — Nay
Carolyn Bosn — Nay
Cavanaugh, J. — Yea
Cavanaugh, M. — Not Voting
Christy Armendariz — Nay
Dan Lonowski — Nay
Dan Quick — Not Voting
Danielle Conrad — Yea
Dave Murman — Nay
Dave Wordekemper — Nay
Dunixi Guereca — Not Voting
Eliot Bostar — Not Voting
George Dungan — Not Voting
Hansen, B. — Nay
Jana Hughes — Nay
Jane Raybould — Not Voting
Jared Storm — Nay
Jason Prokop — Not Voting
John Arch — Nay
John Fredrickson — Not Voting
Kathleen Kauth — Nay
Loren Lippincott — Nay
Margo Juarez — Yea
Megan Hunt — Yea
Merv Riepe — Nay
Meyer, F. — Nay
Meyer, G. — Nay
Mike Jacobson — Nay
Mike Moser — Nay
Myron Dorn — Nay
Paul Strommen — Nay
Rick Holdcroft — Nay
Rita Sanders — Nay
Robert Clements — Nay
Robert Dover — Nay
Stan Clouse — Nay
Tanya Storer — Nay
Teresa Ibach — Nay
Terrell McKinney — Yea
Tom Brandt — Nay
Tony Sorrentino — Nay
Victor Rountree — Yea
Wendy DeBoer — Not Voting
von Gillern — Nay

Official roll call →

Advanced to Enrollment and Review Initial

Passed 35 Yea · 1 Nay · 13 Other
Party YeaNayPresentNot Voting
Unaffiliated 351013
Total 351013
% of votes cast 71%2%0%27%
How each member voted (49)
Member Party Vote
Ashlei Spivey — Not Voting
Barry DeKay — Yea
Beau Ballard — Yea
Ben Hansen — Yea
Bob Andersen — Not Voting
Bob Hallstrom — Yea
Brian Hardin — Yea
Carolyn Bosn — Yea
Christy Armendariz — Yea
Dan Lonowski — Yea
Dan Quick — Yea
Danielle Conrad — Yea
Dave Murman — Yea
Dave Wordekemper — Yea
Dunixi Guereca — Yea
Eliot Bostar — Not Voting
Fred Meyer — Yea
George Dungan — Not Voting
Glen Meyer — Not Voting
Jana Hughes — Yea
Jane Raybould — Yea
Jared Storm — Yea
Jason Prokop — Not Voting
John Arch — Yea
John Cavanaugh — Yea
John Fredrickson — Not Voting
Kathleen Kauth — Yea
Loren Lippincott — Yea
Machaela Cavanaugh — Yea
Margo Juarez — Yea
Megan Hunt — Yea
Merv Riepe — Yea
Mike Jacobson — Not Voting
Mike Moser — Yea
Myron Dorn — Yea
Paul Strommen — Not Voting
R. Brad von Gillern — Not Voting
Rick Holdcroft — Yea
Rita Sanders — Yea
Robert Clements — Yea
Robert Dover — Not Voting
Stan Clouse — Yea
Tanya Storer — Yea
Teresa Ibach — Not Voting
Terrell McKinney — Nay
Tom Brandt — Yea
Tony Sorrentino — Yea
Victor Rountree — Not Voting
Wendy DeBoer — Yea

Official roll call →

Subjects

public-safety health-insurance
Cross-referencing the record. Reading this bill against every other bill in the corpus by meaning, not keywords. Only the first open is slow. It’s instant for you after this. Matching · Ranking · Engrossing

Frequently asked questions

Who sponsors LB 795?
LB 795 is sponsored by Barry DeKay.
What is the current status of LB 795?
This bill has been enacted into law. Introduced January 07, 2026. Enacted.
Where can I track LB 795?
Track LB 795 free on One Click Politics — get push/email alerts when it moves.

Make your voice heard on LB 795

Find the representatives who decide this bill and tell them where you stand — for yourself, or mobilize your whole list in one click with One Click Politics advocacy software.

Find my representatives → Run a campaign

Stay ahead of LB 795

Last checked for changes 3 months ago · updated continuously

One Click Politics tracks every bill in Congress and all 50 states.

Track this bill →